Teligent Inc (NASDAQ:TLGT) Stock Is Shorted More

July 14, 2018 - By Dolores Ford

The stock of Teligent Inc (NASDAQ:TLGT) registered an increase of 2.85% in short interest. TLGT’s total short interest was 7.58 million shares in July as published by FINRA. Its up 2.85% from 7.37 million shares, reported previously. With 1.03 million shares average volume, it will take short sellers 7 days to cover their TLGT’s short positions. The short interest to Teligent Inc’s float is 19.73%.

The stock increased 0.26% or $0.01 during the last trading session, reaching $3.83. About 155,734 shares traded. Teligent, Inc. (NASDAQ:TLGT) has declined 67.87% since July 14, 2017 and is downtrending. It has underperformed by 80.44% the S&P500.

Teligent, Inc., a specialty generic pharmaceutical company, develops, formulates, makes, and markets generic topical, branded generic, and generic injectable pharmaceutical products in the United States and Canada. The company has market cap of $204.95 million. The firm sells generic pharmaceutical products in topical, injectable, complex, and ophthalmic dosage forms. It currently has negative earnings. It also develops, makes, fills, and packages topical semi-solid and liquid products for branded and generic pharmaceutical customers, as well as for over-the-counter and cosmetic markets.

More notable recent Teligent, Inc. (NASDAQ:TLGT) news were published by: Investingnews.com which released: “Pharmaceutical Update: Q2 2018 in Review” on July 10, 2018, also Globenewswire.com with their article: “New Research: Key Drivers of Growth for Webster Financial, Chimerix, Commerce Bancshares, Teligent, Pinnacle …” published on June 29, 2018, Globenewswire.com published: “Teligent, Inc. Announces FDA Approval of Fluocinonide Gel, 0.05%” on June 20, 2018. More interesting news about Teligent, Inc. (NASDAQ:TLGT) were released by: Nasdaq.com and their article: “Teligent, Inc. Announces FDA Approval of Lidocaine and Prilocaine Cream USP, 2.5%/2.5%” published on July 02, 2018 as well as Streetinsider.com‘s news article titled: “Teligent (TLGT) Reports FDA Approval of Fluocinonide Gel, 0.05%” with publication date: June 20, 2018.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

>